People who get GLP-1s are different than those who dont
10.1160/TH12-06-0397 142 TancrediM.RosengrenA.SvenssonA.-M.KosiborodM.PivodicA.GudbjrnsdottirS.et al (2015)
Less common but important risks include dehydration, gallbladder problems, pancreatitis, worsening diabetic eye disease in some patients with rapid glucose improvement, and low blood sugar when used with insulin or sulfonylureas
Lower doses of GLP-1 resulted in lower rate of observable side effects based on a sample of 9,528 Microdose GLP-1 Rx Program users
Immunoproteasome activity 20 g of liver samples from ibuprofen-treated and control animals were incubated with immunoproteasome buffer (50 mM Tris, 5 mM MgCl 2 , 20 mM potassium chloride (KCl), 1 mM DTT (freshly added), pH 7.5), and inhibitor or an equal volume of dimethyl sulfoxide (DMSO) for 20 min at room temperature